News | August 02, 2011

Study Shows Cigarette Smoking Increases Risk of Developing Atrial Fibrillation

August 2, 2011 — Results from a large, United States-based cohort study show that current smokers double their risk of developing atrial fibrillation (AF) compared to people who have never smoked, after more than 13 years of follow-up. The study, published in the August edition of HeartRhythm, the official journal of the Heart Rhythm Society (HRS), indicates a trend towards significantly lower risk of developing AF for those who quit smoking cigarettes versus those who continue to smoke.

According to the HRS, AF is a very common heart rhythm disorder with more than 2 million people in the United States diagnosed and about 160,000 new cases identified each year. While several risk factors have been identified, including obesity, hypertension and diabetes, the association between smoking and AF is less clear.

Between 1987 and 1989, the Atherosclerosis Risk in Communities (ARIC) study enrolled a population-based cohort of over 15,000 black and white participants aged 45-64 years. All participants were questioned at baseline about the number of cigarettes smoked per day, smoking status (current, former or never) and age at smoking initiation or cessation.

Study analysis conducted by Alanna Chamberlain, Ph.D., and co-authors reports 876 incident AF events during an average 13-year follow-up period. The risk of AF was found to be 1.32 times greater among former smokers and twofold higher in current smokers than in nonsmokers. In addition, compared to nonsmokers, former heavy smokers had an 89 percent increased risk of developing AF, while current heavy smokers had a 131 percent increased risk, indicating that quitting smoking lowers the risk of developing AF.  Specifically, there was a 12 percent lower risk of AF among individuals who quit smoking versus individuals who continued smoking.

“AF is a serious health issue that decreases quality of life and significantly increases the risk of stroke,” stated co-author Alanna M. Chamberlain, Ph.D, MPH, department of health sciences research at the Mayo Clinic in Rochester, Minn. “It is my hope that our study findings will shed more light on the impact that smoking has on cardiovascular diseases, and help individuals realize they can play a role in preventing the development of atrial fibrillation.”

These results support previous findings that smoking increases the risk of AF development. The findings also show that associations between smoking and AF do not differ between blacks and whites, despite overall incident rates being lower in blacks. Furthermore, this is the first study to document differences in AF development between participants who remained smokers throughout the study follow-up and those who stopped smoking. Future studies may choose to focus on the role of smoking cessation in the prevention of AF development.

For more information:

Related Content

DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Marijuana Associated With Three-Fold Risk of Death From Hypertension
News | Hypertension| September 14, 2017
Marijuana use is associated with a three-fold risk of death from hypertension, according to research published recently...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Medtronic Announces Japanese Regulatory Approval for In.Pact Admiral Drug-Coated Balloon
News | Drug-Eluting Balloons| September 13, 2017
Medtronic plc announced that the In.Pact Admiral Drug-Coated Balloon (DCB) received approval from the Japanese Ministry...
PQ Bypass Reports Positive Results for Detour System in Patients With Long Femoropopliteal Blockages
News | Peripheral Artery Disease (PAD)| September 13, 2017
A subset analysis of the DETOUR I clinical trial showed promising safety and effectiveness results of PQ Bypass’ Detour...
Overlay Init